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Parasitic diseases affect billions of people and are considered a major public health issue. Close to 400 species
are estimated to parasitize humans, of which around 90 are responsible for great clinical burden and mortality
rates. Unfortunately, they are largely neglected as they are mainly endemic to poor regions. Of relevance to
this review, there is accumulating evidence of the release of extracellular vesicles (EVs) in parasitic diseases,
acting both in parasiteparasite inter-communication as well as in parasitehost interactions. EVs participate
in the dissemination of the pathogen and play a role in the regulation of the host immune systems. Production
of EVs from parasites or parasitized cells has been described for a number of parasitic infections. In this
review, we provide the most relevant findings of the involvement of EVs in intercellular communication,
modulation of immune responses, involvement in pathology, and their potential as new diagnostic tools and
therapeutic agents in some of the major human parasitic pathogens.
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E
xtracellular vesicles (EVs) are key players implica-
ted in intercellular communication without direct
cellular contact. Until very recently virtually un-
known and regarded as by-products of cellular meta-
bolism, the current perception about EVs has changed
drastically due to their newfound role as mediators in the
transmission of biological signals and immune responses
(1,2). These vesicles of various origins can carry as their
cargo a wealth of bioactive molecules such as proteins,
DNA,mRNAs andmiRNAs, through which they can regu-
late their targeted cells.
EVs are small membrane-bound vesicles that are
generally classified in two major types, exosomes and
microvesicles (MVs), based on their size, biogenesis
and composition. Exosomes are 30100 nm vesicles of
endocytic origin that are released after the fusion of mul-
tivesicular bodies (MVBs) with the plasma membrane.
MVs, also sometimes referred to as microparticles (MPs)
or ectosomes, are more heterogeneous in shape, can be
bigger in diametrical size (0.11 mm) and are shed directly
from the plasma membrane (1). The composition of exoso-
mes and MVs does not correspond to a random sampling
of their cell of origin, which implies active sorting of a
specific subset of components including proteins, mRNAs,
miRNAs and lipids. Exosomes, for example, are enriched
in proteins of the endosomal pathway and proteins in-
volved in vesicle formation (3), while proteins from
organelles such as the nucleus and endoplasmic reticulum
are not commonly found in these vesicles (4). The lipid
composition of EVs is different from that of the plasma

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membrane. Both exosomes and MVs contain higher levels
of amino phospholipids and the asymmetrical distribution
of phosphatidylethanolamines is lost (5,6). Exosomes are
enriched in ceramide (7) but not in lysobisphosphatidic
acid (6,8). Also, the composition and morphology of
exosomes are clearly distinct from those of apoptotic
bodies (9). However, a clear discrimination between exo-
somes and MVs in terms of their composition is still
difficult as there is an overlap of detected components
and physical properties (1,10,11). On-going efforts of
EV characterization have demonstrated that besides a
common set of components, vesicles also feature cell-
type-specific subsets, which complicate their biochemical
characterization. Furthermore, confusion on the nomen-
clature and the origin of EVs in the literature, as well
as differences in the isolation methodologies make it
difficult to fully differentiate EV types (1).
Parasites have plagued humans since their appearance
and migration throughout the world around 150,000 years
ago (12). In fact, the existence of parasitism was likely
described in ancient papyrus dating 3,0004,000 years
ago, but it was not until the beginning of the renascence
period that descriptions of human infections undoubtedly
related to parasitism were reported. It is believed that
close to 400 species can affect humans, of which around
90 are responsible for great clinical burden and mortality
rates. There is accumulating evidence of the release of
EVs in parasitic diseases, acting both in parasiteparasite
inter-communication as well as in parasitehost interac-
tions (1315). Production of EVs from parasites or para-
sitized cells has been described in a number of parasitic
infections (Table I). The world of human parasites,
however, is so vast that for simplicity, and following the
division suggested by Cox (12), we have divided them in
2 large groups: parasitic protozoa and helminths.
EVs and parasitic protozoa
Literarily meaning ‘‘first animals,’’ protozoa are a rather
complex group of organisms commonly divided into 4
major groups according to their locomotion: amoeba,
flagellates, ciliates and sporozoa. With circa 11,000 differ-
ent species, 70 affecting humans, parasitic protozoa are a
diverse group of unicellular eukaryotic organisms display-
ing complex life cycles often alternating between different
hosts. Diseases such as amoebiasis, malaria, African and
American trypanosomiasis, as well as leishmaniasis are
responsible for hundred millions of clinical cases every
year in different countries around the world (Fig. 1). Here,
we will concentrate on two major groups from which data
on EVs is rapidly growing: apicomplexa and kinetoplastids.
Apicomplexa
The apicomplexa is a large and diverse phylum of unicel-
lular parasites of animals characterized by the presence
of an organelle of endosymbiotic origin, the apicoplast,
and an apical complex composed of secretory organelles
called rhoptries and micronemes involved in cell invasion.
The apicomplexa are composed of more than 5,000 named
species of which 7 genera infect humans: Plasmodium,
Babesia, Cryptosporidium, Isospora, Ciclospora, Sarcocystis
and Toxoplasma (16,17).
Plasmodium spp.
Malaria is a parasitic disease caused by apicomplexan
protozoa of the genus Plasmodium and is transmitted
to humans through the bite of the female mosquito
Anopheles. Four species of Plasmodium account for the
disease (P. falciparum, P. vivax, P. malariae and P. ovale),
with a fifth species, P. knowlesi, recently identified from a
zoonotic phenomenon (18). According to WHO estimates,
in 2012 there were close to 207 million clinical cases and
an estimated 627,000 deaths (19). In addition, several
species of Plasmodium exist that can infect other animal
species such as birds, reptiles, monkeys and rodents (20
22). In humans, the parasite develops silently in the liver
before reaching the blood stage, where malaria parasites
invade and replicate within host red blood cells. A
proportion of parasites will convert to gametocytes, the
sexual stages that are capable of transmitting the infec-
tion to the insect vector.
In malaria, the release of EVs from different cells has
been described in murine models as well as in human
infections. Different human studies have demonstra-
ted that the circulating levels of EVs rise during infec-
tions by the human parasites Plasmodium vivax (23) and
Plasmodium falciparum (2426). In these studies, the
levels of circulating EVs correlated with clinical manifes-
tations such as fever and cerebral dysfunctions, suggest-
ing a role of EVs in malaria pathogenesis. Studies in mice
models suggest that EVs contributed to the induction
of systemic inflammation (27,28). In the murine malaria
model of mice infected with Plasmodium berghei (ANKA
strain), a reference strain from African origin in which
mice, albeit variably, develop cerebral malaria (CM), EVs
isolated from plasma, primarily derived from infected
erythrocytes, induced a potent activation of macrophages
via toll-like receptors (TLR) when compared to plasma-
derived MVs from naı¨ve animals (28). In the same murine
model, the abrogation of MV formation in mice knocked
out for the gene ABCA1 protected these animals against
CM, demonstrating a link between EV production and
pathogenesis (29). The ABCA1 transporter is a mod-
ulator of the presence of phosphatidylserine (PS) in the
outer layer of the plasma membrane, and PS is a major
component of the surface of MVs.
Exosomes have also been described in the context of
malaria infection in the mice model Plasmodium yoelii
17X-BALB/c. In this non-lethal malaria murine model, the
parasites present a tropism for reticulocytes, resembling
the human malaria infection by P. vivax. Exosomes were
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Table I. Extracellular vesicles in parasites
Parasitic pathogen Type of vesicle Characterization Diameter (mean or range) References
Protozoa
Apicomplexa Plasmodium falciparum Plasma-derived microvesicles FC n.d. (2426)
Exosome-like vesicles EM, AFM 70120 nm (31)
Erythrocyte-derived microvesicles SG, EM, WB, MS/P 100400 nm (32)
Plasmodium vivax Plasma-derived microvesicles FC n.d. (23)
Plasmodium berghei Plasma-derived microvesicles EM, FC 75450 nm (27)
EM 150250 nm (28)
Plasmodium yoelii Exosomes from infected reticulocytes SC, EM, FCb, MS/P 30120 nm (30)
Toxoplasma gondii Exosome-like vesicles EM, WB 60150 nm (39)
EM/m@ 8090 nm (43)
Cryptosporidium parvum Exosomes EM, WB, NTA 40100 nm (44)
Kinetoplastids Trypanosoma brucei Exosome-like vesicles SG, EM, MS/P 50100 nm (48)
Trypanosoma cruzi Plasma membrane-derived vesicles, exosomes, ectosomes EM 500 nm (50)
EM n.d. (72)
EM 2080 nm (51)
EM n.d. (49)
EM, WB B1,000 nm (52)
SG, EM, WB, NTA, MS/P 7090 nm, 130140 nm (87)
EM, NTA, DS 130140 nm (92)
EM, NTA, MS/L 7090 nm, 130140 nm (94)
EM, DS 20200 nm (91)
EM, EA 40500 nm (95)
T. cruzi-induced host cell plasma-membrane-derived vesicles SG, EM, FC 200500 nm (89)
Leishmania spp. Exosomes EM, MS/P 50 nm (97)
SG, EM, WB 3070 nm (98,99)
SG, EM, MS/P, WB B100 nm (103)
Leishmania-induced macrophage exosomes SG, EM, MS/P, WB 40100 nm (100)
Other Trichomonas vaginalis Parasite-derived exosomes SG, EM, WB, NTA 50100 nm (106)
Giardia duodenalis Extracellular vesicles FC n.d. (107)
Helminth
Flatworms Echinostoma caproni Membrane-bound vesicles EM, MS/P 30100 nm (112,113)
Fasciola hepatica Exosome-like vesicles EM 30100 nm (122)
Dicrocoelium dendriticum Exosome-like vesicles EM, MS/P, DS 30100 nm (127)
Roundworms H. polygyrus Extracellular vesicles EM, m@ 50100 nm (129)
FC: flow cytometry; SG: sucrose gradient; SC: sucrose cushion; EM: electron microscopy; WB: western blotting; NTA: nanoparticle-tracking analysis; AFM: atomic-force microscopy; FCb:
flow cytometry of bound-to-beads vesicles; MS/P: mass spectrometry/proteomics; MS/L: MS/lipidomics; DS: deep sequencing or RNA-seq of small RNAs; EA: enzymatic assay; m@:
microarrays.
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isolated from plasma of mice and from reticulocyte cul-
ture by differential centrifugation and their identity was
confirmed by electron microscopy, FACS and proteomic
analyses. The study demonstrated that exosomes derived
from infected reticulocytes contained host and parasite
proteins and had a role in modulating immune responses
(30). Parasite proteins within the exosomes included several
antigens such as merozoite surface proteins 1 and 9, as
well as blood stage surface antigens and enzymes related
to proteolysis and metabolic processes. Immunizations of
BALB/c mice with exosomes from infections, isolated
both from peripheral blood and from reticulocyte in vitro
cultures, elicited IgG antibodies capable of recognizing
P. yoelii-infected red blood cells (iRBCs), induced reti-
culocytosis and changed the cell tropism to reticulo-
cytes of the normocyte-prone lethal P. yoelii 17XL strain
upon infection. Moreover, when combined with CpG-
oligodeoxynucleotides, immunizations conferred complete
and long-lasting protection against lethal infections in
close to 85% of the mice tested. These data thus showed
for the first time that exosomes derived from reticulocytes
could be explored as a vaccine and platform against
malaria infections (30).
More recently, two publications have implicated EVs
as mediators of intercellular communication in malaria.
Both studies show that P. falciparum-infected erythro-
cytes shed vesicles, that these vesicles contain host as well
as parasite-derived proteins and that they are transferred
to other iRBCs in vitro (31,32). Apart from their overall
concurrence, these studies have important distinctions that
are worth mentioning before further detailing of their
findings. In the work by Regev-Rudzki et al., the authors
have used OptiPrepTM followed by atomic force micro-
scopy to describe the release of exosome-like vesicles of
80120 nm by ring-stage parasites (31), whereas Mantel
et al. describe slightly larger vesicles in the range of
100400 nm, isolated by ultracentrifugation in a sucrose
cushion and measured by electron microscopy, with the
timing of release of a subpopulation of 150250 nm coin-
ciding with the moment of schizogony or shortly after (32).
According to Mantel et al., iRBCs produce 10 times
more EVs than uninfected RBCs, corroborating previous
results that described a 13-fold increase in the production
of EVs both in in vitro conditions as well as during
P. falciparum infections (24). Proteomic analysis of these
EVs showed no apparent difference in host-derived protein
Fig. 1. Endemic geographical distribution of some human parasitic diseases. The map shows 5 different areas of the world according to
WHO: Americas, Africa, Europe, Eastern Mediterranean and South-East Asia Western Pacific. The percentages represent the
distribution of autochthonous endemic cases (133).
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content between uninfected and infected RBCs. Immuno-
blotting with immune sera from malaria patients revealed
the presence of parasite antigens in iRBC-derived EVs
and mass spectrometry identified over 30 parasite proteins,
mainly Maurer’s clefts residents and surface proteins, but
no markers of the knob complex were identified. The
iRBC-derived EVs showed strong inflammatory pro-
perties, inducing cytokine production in macrophages
and PBMCs, activating neutrophils and increasing their
migration rate (32).
In the work by Regev-Rudzki et al., exosome-like vesi-
cles were shown to promote the transference of genetic
material between iRBCs, demonstrating a novel mecha-
nism for cell-to-cell communication between parasites.
Transgenic P. falciparum lines resistant to either blasticidin
or WR99210, but not both, were co-cultured in the
presence of the 2 drugs and doubly resistant parasites
were observed after a few days in culture, whereas the
individual lines did not thrive under combined drug
treatment. After discarding the possibility of plasmodial
DNA uptake from the medium, the involvement of EVs
was demonstrated by growing the parasite lines in
different compartments of a transwell with 400 nm pores.
In this setting, even without direct cell-to-cell contact,
doubly resistant parasites were still recovered. Of note,
the transference of resistance was unidirectional, always
with the selection cassette for blasticidin being trans-
ferred as the donor. Deletion of PfPTP2, a protein that
localizes to membranous structures budding fromMaurer’s
clefts, significantly reduced both the production of EVs
and the capacity of the parasite line to receive a donor
plasmid through EVs of other lines, implicating this
protein in the mechanism by which iRBCs communicate
via exosome-like vesicles (31). Interestingly, Mantel et al.
also demonstrated a connection to the Maurer’s cleft
even though the type of EVs recovered and their stage of
production during the asexual cycle were different.
Perhaps, most intriguingly is the fact the 2 studies have
independently demonstrated a connection between iRBC-
derived EVs and gametocytogenesis. Gametocytogenesis
is the process by which a fraction of the circulating para-
sites abandon asexual replication and differentiate into
sexual stages, the gametocytes, that will ensure parasite
transmission through the invertebrate host, a female
anopheline mosquito (33). In both studies, the rate of
formation of sexual stages was positively altered, in a
titrable fashion, by the addition of EVs from iRBCs. The
switch to sexual commitment responds to environmental
cues, and the involvement of parasite-derived factors,
capable of diffusing through a membrane with 200 nm
pores, has been previously described (34,35). However,
the nature of these factors remains unknown and the data
on EVs from these 2 studies could provide a plausible
explanation. Whether these findings have relevance for
the dynamics of asexual/sexual balance in infections
remains to be demonstrated (36).
The role of EVs in malaria pathogenesis has also been
highlighted very recently in an article using a rodent-
malaria model of CM. Previous studies had demon-
strated elevated levels of MPs in patients with CM (24)
and ablation of a transporter implicated in the release of
MPs conferred protection against CM in a murine model
(29). These results suggested a role of MPs in the patho-
genesis of CM but a direct demonstration of this role was
missing. Combes and co-workers studied the fate and
distribution of MPs in mice models of CM and non-
cerebral malaria (NCM). Firstly, they determined the
concentration of MPs in each model and showed that
there were elevated levels of MPs in mice developing CM
in contrast to NCM mice. Moreover, they showed that
MPs production coincides with CM onset, production of
cytokines and chemokines up-regulation of adhesins and
binding of vascular cells to MVs. Next, they determined
the fate of fluorescently labelled MPs in the peripheral
blood of animals after intra-venous injection. As ex-
pected, MPs were rapidly and mostly cleared from
circulation by yet to be identified spleen cells within the
red pulp. Of interest, histopathological analysis of brain
smears from all recipient mice showed that only MPs
from P. berghei-infected mice were found within the brain
microvessels of CM mice. Most relevant, transfer of TNF
generated endothelial cell-derived MPs produced in vitro
induced CM-like pathology in healthy mice (37). All
together, these data show for the first time a connection
between MPs and the pathogenesis of CM. Whether
these findings will translate into novel prognostic markers
and/or therapies for this clinical syndrome remains to be
determined.
Toxoplasma and Cryptosporidium species
In addition to Plasmodium spp., studies on EVs and
exosomes of other apicomplexa have been reported.
Toxoplasma gondii is an obligate intracellular parasite
that causes a disease called toxoplasmosis that infects
humans and domestic animals throughout the world (38).
In humans, it causes serious damage during pregnancy
and in immunocompromised patients, it can also lead to
severe clinical complications including death. Noticeably,
pioneering studies on the use of exosomes as therapeutic
agents against parasitic diseases were first reported in
T. gondii (39). Immortalized dendritic cells were pulsed in
vitro with T. gondii antigens and exosomes obtained from
culture supernatants. T. gondii-tagged exosomes were used
in immunizations of mice and then challenged with lethal
and sub-lethal doses. Immunized mice elicited potent and
specific humoral and cellular immune responses against
T. gondii and close to 70% of the mice challenged with
a lethal dose were protected. Mice challenged with a
sublethal dose revealed significantly lower number of
EVs in parasitic diseases
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cysts in the brains of the animals examined. These results
were thus the first to demonstrate that, similar to DCs
primed with tumour antigens (40), DCs pulsed with para-
site antigens were capable of eliciting protective immune
responses. Stimulation of pro-inflammatory responses was
later reported in vitro and in vivo with exosomes obtained
from T. gondii-infected macrophages (41) and the pro-
tective efficacy of DC-derived tagged exosomes further
demonstrated in a mouse model for pregnancy (42).
Recently, the presence of exosome-like vesicles obtained
from supernatants of Toxoplasma-infected human fore-
skin fibroblasts has also been reported (43). Of interest,
unique expression profiles of RNA-cargo of yet uniden-
tified origin and function were observed.
Cryptosporidium parvum is an obligate opportunistic
intracellular pathogen, recognized as a major cause of
diarrhoea in AIDS and immunodepressed patients often
resulting in death. Previous studies had demonstrated
that infection by C. parvum elicited a TLR-4-dependent
pathway for regulating transcription of miRNAs to con-
trol parasitism (44). Remarkably, a search for mechanistic
insights revealed that infection stimulated the release of
host intestinal epithelial exosomes shuttling anti-parasite
peptides. Thus, this study represents the first report to
implicate the release of exosomes from intestinal lumi-
nal cells as an important mechanism to control gastro-
intestinal parasitic infections.
Kinetoplastids
The kinetoplastids are flagellated unicellular organisms
characterized by the presence of the kinetoplast, a net-
workof circular mitochondrial DNA, with many copies of
the mitochondrial genome (45). They parasitize virtually
all vertebrate species as well as insects and plants, and are
transmitted by insects, where they complete their biolo-
gical cycle. A group of kinetoplastid protozoan parasites,
known as trypanosomatids, which are characterized by
possessing a single flagellum, affects millions of people
worldwide. The major pathogenic trypanosomatids for
humans are: Trypanosoma brucei or African trypano-
somes, which cause sleeping sickness or human African
trypanosomiasis (HAT); Trypanosoma cruzi, which causes
Chagas disease or American trypanosomiasis; several
species of the genus Leishmania, which provoke a wide
spectrum of diseases with different pathological manifes-
tations, collectively known as leishmaniasis; T. cruzi and
Leishmania spp. have obligatory intracellular cycles in the
definitive host, whereas T. brucei remains as an extra-
cellular parasite while infecting humans. All trypanoso-
matids are polymorphic, with different forms that appear
during the biological cycle in the insect or in the verte-
brate, and undergo a strong physiological adaptation with
biological changes in the passage from the insect vector to
the blood of the definitive host, during the internalization
to the cell cytoplasm or vice versa (45).
Trypanosoma spp.
The genus Trypanosoma contains many species, most
causing major veterinary diseases but two of them, that is,
Trypanosoma cruzi and Trypanosoma brucei, are respon-
sible for two of the most neglected human diseases,
Chagas disease and African trypanosomiasis. T. brucei
and T. cruzi are flagellates that share many biochemical
pathways and specific subcellular organelles, such as
glycosomes and kinetoplast (46,47). Trypanosomes are
able to produce and release different types of vesicles into
the extracellular milieu that play important roles in the
parasitehost interaction, presumably by enabling patho-
gen survival and replication within the host (4851).
These vesicles can interact directly with host target cells,
exert long-distance effects on the host immune system,
and promote life-cycle transitions within their own
population (52).
Two subspecies of T. brucei, that is, T. b. gambiense and
T. b. rhodesiense, cause sleeping sickness or HAT, which is
transmitted by tsetse flies (Glossina spp.). It is lethal when
untreated and is a threat for over 60 million people living
in sub-Saharan countries. After a long period of increasing
prevalence, now HAT incidence seems to be decreasing
(5355). T. brucei spends its entire cycle as an extra-
cellular parasite, fully exposed to the host immune system
and, therefore, it has developed survival strategies, anti-
genic variations, among others.
For a better understanding of the pathogenic process
and the survival strategy of T. brucei, some proteomic
approaches have begun to characterize the proteins secre-
ted by this parasite. In 2010, Geiger et al. provided the first
overview of the proteins secreted by bloodstream forms
of different strains (i.e. Feo, OK, and Biyamina) of T.
brucei gambiense. With the use of liquid chromatography
electrospray ionization tandem mass spectrometry (LC
ESI MS/MS), 444 proteins were identified. Notably, a
significant proportion of proteins in the secretome lacked
a transit peptide, suggesting they are not secreted through
a classical sorting pathway. Moreover, the authors found a
proportion of vesicles with the same size and density as
exosomes, and with some proteins in common. EVs were
isolated and characterized from secreted material as well
as from infected rat sera, confirming an active budd-
ing process on the plasma membrane (48). In addition,
proteomic analysis of the secretome isolated from the
procyclic form (tsetse fly) revealed a spectrum of proteins,
the majority of which belong to 14 families of proteases.
These proteases may be required for every aspect of the
parasite’s life cycle, from the modification of the physio-
logical environment to the immune evasion (56). The
secretion of proteins via this new pathway may have
several advantages for trypanosomes, such as delivering an
avalanche of new epitopes to overwhelm the host immune
system, or establishing a communication link between
parasites as a survival strategy. These findings may open
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6
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2014, 3: 25040 - http://dx.doi.org/10.3402/jev.v3.25040
new approaches to formulate novel strategies for control-
ling the parasites and the disease.
Trypanosoma cruzi causes Chagas disease, a neglected
tropical infection endemic to Latin America, where it is
transmitted mostly to humans in the faeces of triato-
mine bugs, known as ‘‘kissing bugs’’ (46). However, other
forms of transmission are vertical transmission (conge-
nital), blood transfusion, organ transplantation, and oral
contamination via tainted fluids and foods. Outbreaks
of the disease through oral transmission, causing the
acute form of Chagas disease, are exponentially increasing
(57,58). The disease affects almost 810 million people in
South America, and an estimated 50,000200,000 new
cases are confirmed every year (59), with an increasing
number of cases reported in non-endemic regions, in-
cluding the United States, Canada, Europe and some
Western Pacific countries, due to human migratory
currents from endemic countries (6062). The course of
the disease is marked by 2 phases: an acute phase with a
mortality rate of approximately 5%, and a chronic phase
38 weeks after the onset of the illness, which remains
asymptomatic for a long time; in fact only 2030% of
cases ever develop any symptoms related to the disease.
In contrast to the other human trypanosomes, T. cruzi
has an obligate intracellular multiplication phase, the
amastigote form, which protects the parasite from the
humoral immunity, as well as the trypomastigote form in
the bloodstream (63).
In 1979, da Silveira et al. (50) were the first to
demonstrate the secretion or shedding of MVs by T.
cruzi. These vesicles were obtained from non-infective
epimastigote forms following parasite incubation with
cross-linking reagents or acid pH buffers/solutions, and
purification by ultracentrifugation followed by sucrose
gradient. Transmission electron microscopy (TEM) and
freeze-fracture experiments showed that epimastigote
vesicles were derived mainly from the plasma membrane
and flagellar pocket. Interestingly, these authors also
demonstrated by SDS-PAGE, stained with periodic acid-
Schiff, that epimastigote-derived vesicles were rich in
glycoconjugates, named bands A, B, C and D, previously
described by Alves and Colli (64). Later, these molecules
were fully characterized and proven to be major glyco-
proteins (mucins, bands AC) (6567), glycolipids
(lipopeptidophosphoglycan-LPPG or glycoinositolpho-
spholipids-GIPLs) (68) and glycopeptides (NETNES)
(band D) (69) of the parasite surface.
Plasma membrane-derived vesicles were later shown
by Gonc¸alves et al. to also be spontaneously shed by
infective host-cell-derived trypomastigote (TCT) forms of
T. cruzi. These authors clearly demonstrated that the shed-
ding process was temperature and time-dependent, inde-
pendent of the presence of proteins in the culture medium,
and happened in different parasite strains analysed.
Interestingly, that report also described the use of size-
exclusion chromatography (in Sepharose-4B) for the puri-
fication of [35S]-methionine-labelled parasite EVs (51).
Immunoprecipitation experiments of these labelled mole-
cules revealed that Tc-85, a member of the trans-sialidase
(TS)/gp85 glycoprotein superfamily involved in host-
cell adhesion and invasion by the parasite (70,71), was
a major component of the shed EVs. TEM results also
showed that the TCT-derived EVs ranged from 20 to 80 nm
in diameter, resembling therefore exosomes. In fact, the
expression of Tc-85 in EVs shed by trypomastigote stage,
mainly from its flagellar pocket, had been previously
reported by Ouaissi et al. (72). Subsequently, Ouaissi
et al. (49) also described that the major T. cruzi flagellar
24-kDa antigen, currently known as flagellar calcium-
binding protein (FCaBP) (73), was also secreted in EVs
derived from the plasma membrane and flagellar pocket
of infective trypomastigote forms. Together, the afore-
mentioned reports clearly pointed out the importance
of shedding of EVs as a novel mechanism used by the
parasite to deliver or present major antigens to host cells.
Recently, preliminary proteomic analysis of the TCT-
derived EVs has shown that these EVs are enriched in
glycoproteins of the TS/gp85 superfamily, a-galactosyl-
containing glycoproteins, proteases (i.e. cruzipain), cytoske-
leton proteins, mucin-associated surface proteins (MASP)
and others (74,75). Many of these proteins are involved in
the processes of adhesion and cell invasion (76,77), some
of which are specific proteins of Trypanosoma cruzi.
Shed vesicles could represent an additional mechanism
by which invading T. cruzi parasites systematically present
their antigens to the host. The TS/gp85 glycoproteins,
MASP, and mucins found in EVs are associated with the
plasma membrane via glycosylphosphatidylinositol (GPI)
anchor, and represent the major antigens expressed on the
plasma membrane (74,75,78). GPI-anchored glycopro-
teins protect parasites against the immune system bymodu-
lating the host immune response mediated by cytokines
and/or forming a dense glycocalyx coat, which hampers
the destruction of the parasite by lytic, protective anti-
a-galactosyl antibodies (7883). T. cruzi EVs, which
contain bioactive molecules, can also play a role in the
interaction with the host cells, determining the suscepti-
bility to infection of mammalian cells.
Trans-sialidases are involved in the transfer of sialic
acid from host glycoconjugates to the parasite surface
mucins, as well as to gp85 glycoproteins (71). The activity
of TS assists the parasite in several functions, including
parasite survival, infectivity, and host-cell recognition
(70,80). Other members of the gp85/TS glycoprotein
family, such as the Tc85 sub-family, are involved in T.
cruzi adhesion (77,84,85). These molecules and others,
like gp82 or gp90, have been proposed to mediate the
parasite interaction with host cells, playing a role in host-
cell invasion (58). Mucins, the other abundant sugar-
containing compounds, induce both cellular and humoral
EVs in parasitic diseases
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responses, as well as the activation of cells through the
TLR 2 (75,78,82,86).
Experiments injecting EVs into BALB/c mice prior to
T. cruzi infection showed effects on the course of the
infection (52). EVs were obtained through Sepharose
CL-4B chromatography and a-galactosyl (a-Gal)-positive
fractions were pooled and their biochemical analysis
revealed the presence of highly abundant surface glycopro-
teins, such as TS, Tc85, and cruzipain. Treated animals
developed severe heart pathology with an intense inflam-
matory reaction and a higher number of amastigote nests
(52). Thus, EVs can interact with the host-cell surface or
be internalized, preparing the microenvironment for the
incoming trypanosome, supporting their potential role in
virulence and pathogenesis.
Recently, the individual proteomes of 2 EV populations
from the non-infective epimastigote and the infective
metacyclic trypomastigote forms of T. cruzi have been
described (87). This study provided evidence supporting
the existence of at least 2 mechanisms of vesicle secretion
in T. cruzi: exocytic fusion ofMVBs resulting in exosomes,
and budding of vesicles directly from the plasma mem-
brane, resulting in MVs (ectosomes or plasma membrane-
derived vesicles). Using a combination of methods,
including morphological (TEM), immunochemical, and
label-free quantitative proteomic analysis, the authors
demonstrated that distinct proteins are enriched in each
vesicle population, revealing a rich collection of excreted/
secreted molecules involved in trafficking and membrane
fusion, metabolism, signalling, nucleic acid binding, and
parasite survival and virulence (87). These results pro-
vided the first insight in the search for potential protein
markers for each population of the EVs.
Bayer-Santos et al. (87) have also shown how EVs may
be used by infective metacyclic trypomastigotes to deliver
cargo into mammalian (HeLa) cells. EVs from T. cruzi
infective forms can either be released inside the mamma-
lian cells or endocytosed by cells after their release in the
medium. Once T. cruzi-derived EVs reach the host-cell
cytoplasm, they likely modulate host cells to support
parasite survival and replication. Moreover, the release of
bioactive molecules in EVs may be an efficient strategy
employed by the parasite to protect these biomolecules
against extracellular degradation or serving as decoys
against the highly abundant lytic anti-a-Gal antibodies
(82,83,88). An additional immune evasion mechanism of
T. cruzi relies on the ability of trypomastigote forms to
induce the release of host cell-derived vesicles, which
contribute to immune evasion by protecting the parasite
from the complement attack, and ultimately resulting in
increased parasite infectivity and survival (89).
As mentioned above, both T. cruzi and T. brucei have
complex life cycles. To survive changing environmental
conditions, parasites must undergo rapid and significant
changes in gene expression, which are achieved essentially
at the post-transcriptional level through modulation of
mRNA stability and translational control mechanisms.
Over the last decade, an expanding family of small regu-
latory RNAs (miRNAs, small interfering RNAs, and
Piwi-interacting RNAs) was recognized as key players
in novel forms of post-transcriptional gene regulation in
many eukaryotes (90). Notably, stressed epimastigotes
shed high levels of vesicles (20 to 200 nm in diameter) to
the extracellular medium, which carry small tsRNAs and
TcPIWItryp proteins as cargo (91). Moreover, at least a
fraction of EV cargo was transferred between parasites and
susceptible mammalian cells, but not to non-susceptible
cells. These data suggest that EVs shed by T. cruzi
mediate parasite-parasite communication by promoting
metacyclogenesis, thus assuring parasite survival through
the emergence of the infective form, as well as increasing
the susceptibility of mammalian cells to infection (91). The
presence of varying and differentially expressed small
RNAs by non-infected epimastigotes and infective meta-
cyclic trypomastigotes has also been recently reported
(92). More recently, it has been demonstrated that both
T. cruzi-derived EVs and tRNA-derived small RNAs
found in T. cruzi EVs are able to up- or down-regulate a
variety of host-cell genes (93). All together, these results
indicate that small RNAs play an as yet to be fully
defined regulatory role(s) in T. cruzi infections.
More recently, a focused lipidomic analysis of all four
T. cruzi developmental stages revealed a lysophosphati-
dylcholine (LPC) containing C18:1 fatty acid, which has
platelet activating (PAF)-like factor activity (94). Inter-
estingly, the bioactive C18:1-LPC species is also secreted
to extracellular medium and can be found in larger EVs
(ectosomes) secreted by infective metacyclic trypomasti-
gote forms. The authors proposed that T. cruzi-derived
C18:1-LPC, but not other parasite LPC species lacking
PAF-like activity, could eventually be involved in some
key aspects of the pathophysiology of Chagas disease,
including increased platelet aggregation related to myo-
carditis, focal ischemia, and myonecrosis.
Neves et al. (95) have recently shown that T. cruzi
trypomastigote-derived EVs contain acid and alkaline
phosphatase activities, which can increase the parasite
capacity to adhere and infect host cells.
Leishmania spp.
Leishmaniasis are diseases caused by more than 20 species
of parasites of the genus Leishmania and transmitted to
their host by the bites of sandfly mosquitoes Phlebotomus
and Lutzomyia. It is calculated that around 12 million
people from 98 different countries are currently infected.
There are 3 main forms of the disease: cutaneous which
causes localized skin ulcers, visceral which is the most
severe form infecting vital organs, and mucocutaneous
which causes irreversible destruction of membranes in the
nose, mouth and throat (96).
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The presence of exosome-like vesicles in Leishmania
donovani was originally suggested after analysing the
proteome of supernatants obtained from infected macro-
phages cultures. The absence of the classical secretion
signal in the majority of the parasite proteins identified
indicated the use of non-classical targeting mechanisms
to direct protein export (97). On the other hand, the
presence of proteins previously identified in exosomes led
the authors to propose a model in which protein export
occurs largely through the release of MVs. Secretion of
exosomes was confirmed in the growth medium from
cultured L. donovani, L. mexicana and L. major species.
Of interest, exosome release was found to be sensitive
both to temperature and pH. Moreover, using fluorescent
labelling of Leishmania surface proteins (such as leish-
manolysin GP63, which was consistently present in
Leishmania exosomes) as well as Leishmania expressing
green fluorescent protein (GFP), they found an uptake of
fluorescent vesicles by non-infected cells, with accumula-
tion of GFP and parasite proteins in structures consistent
with MVBs in the cytosol of infected macrophages.
Also, it was shown that this intracellular communication
selectively induced secretion of IL-8, thus demonstrating,
for the first time in parasitic protozoa, that exosomes
constitute cargo machinery for intercellular communica-
tion and modulation of immune responses (98).
It has also been demonstrated that exosomes released
by Leishmania spp. modulate the cytokine production by
human monocytes and the phenotype of dendritic cells,
having a predominantly immunosuppressive effect pro-
moting IL-10 production and inhibiting and regulating
the TNF-a and IFNg that promote parasite progression
(99). In addition, the comparisons of the proteome of
uninfected, infected, and the LPS-stimulated cell line of
macrophages have corroborated the differential parasite
cargo specificity in exosomes derived from these cells, and
also identifying for the first time the surface protease
GP63, specific from Leishmania, in exosomes released by
cells infected with the protozoa (100). GP63 is a metallo-
protease present on the surface of the promastigote and
amastigote forms, which actively participates as a critical
virulence factor of Leishmania, as well as in immunomo-
dulating the host response. Evidence suggests that exo-
somes secreted from Leishmania-infected cells, which
contain the virulence factor GP63, when delivered to
hepatocytes, can down-regulate the production of specific
host miRNAs, thus facilitating liver infection (101).
Similar to Toxoplasma gondii (39), the use of dendritic
cells-derived exosomes loaded with L. major antigens in
combination or not with CpG, conferred protection in
experimental infections of Balb/C mice (102). Mice were
immunized with DC-derived exosomes i.v. and 1 week
later challenged with 5105 stationary-phase promasti-
gotes in the right hind footpad. Protection was defined in
terms of size of lesions developed in the right footpad as
compared to the non-infected footpad and in terms of
parasitized cells in the lymph nodes draining the site of
infection. The size of the lesion was significantly smaller
and approximately 200-fold less cells were found in BMDC-
derived exosomes vaccinated animals in contrast to
controls. Of note, CpG was not required for conferring
protection. These results further reinforced the value of
exosomes as cell-free vaccines against Leishmania.
Recently Hassani et al. have demonstrated using WT
and KO forms of GP63, that the enzyme present in the
exosomes can modulate the macrophage immune re-
sponse at both signalling and gene-expression levels. WT
exosomes seem to regulate gene expression of IFNg and
IL-12 receptors, as well as TLR2 and TLR8, inducing the
production of iNOS. The KO exosomes seem to be more
pro-inflammatory than their WT counterparts. Further-
more, GP63 seem to participate in exosomal protein
sorting in the parasite (103).
Other human parasitic protozoa
Trichomonas vaginalis
The urogenital extracellular parasite Trichomonas vaginalis
is the causative agent of trichomoniasis, themost prevalent
sexually transmitted infection, and affecting 275 million
people every year. Early studies of the surface membrane
proteome of T. vaginalis revealed the presence of at
least 3 tetraspanins (Tsps) (104,105). As some Tsps are
well known constitutive components of exosomes, it was
suggested that this extracellular parasite could secrete
Tsps-containing exosomes facilitating colonization of the
urogenital tissue. To demonstrate the presence of Tsps-
exosomes in T. vaginalis, they constructed transgenic
parasites expressing HA-tagged Tsp1 and showed their
presence in the plasma membrane as well as in the cyto-
plasm of parasites in MVBs structures (106). The vesicles
purified from the parasite growth media exhibited the
characteristics of exosomes. The characterization of the
proteome of these exosome-like vesicles demonstrated that
T. vaginalis exosomes contained parasite Tsps as well as
proteins previously shown to be involved in pathology.
In addition to their protein cargo, T. vaginalis exosomes
also contain a yet uncharacterized small RNAs ranging
from 25 to 200 nt. Noticeably, labelled exosomes were
shown to interact with and deliver their content to host
cells, and tomodulate the production of cytokines IL6 and
IL8. Moreover, exosomes from a highly adherent strain
induced strong parasite attachment of a less adherent
strain to epithelial cells (106). These studies thus convin-
cingly demonstrate that T. vaginalis uses exosomes in host
cell colonization.
Giardia duodenalis
Giardia duodenalis is an extracellular parasite of the
human intestine with high global prevalence (20% in
EVs in parasitic diseases
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developing countries) causing diarrheal illness in indivi-
duals from both developing and industrialized countries.
Deolindo et al. have reported an increase in G. duodenalis
EVs formation in response to different conditions (i.e.
pH changes, presence of bile, etc.), suggesting that these
vesicles could provide a mechanism to the parasite to
adapt to the host changing environment in the course of
the infection (107). A recent study has characterized the
proteome of the vesicles produced during G. duodenalis
encystation, a process that seems to be mediated by these
vesicles, supporting the formation of a low complexity
extracellular matrix (108).
EVs in parasitic helminths
Helminths infections are considered neglected tropical
diseases. The high medical, educational, and economic
burden of helminths infections, together with their coen-
demicity with malaria and AIDS, provides an important
rationale for launching a global assault on parasitic
worms. Helminths can be divided into 2 major groups
known as the nematodes (roundworms) and the Platyhel-
minthes (flatworms), the latter composed by the cestoda
(tapeworms) and trematoda (flukes) (109). Together, they
are responsible for a large burden of disease and socio-
economic losses, as hundreds of millions of people mostly
in areas of extreme poverty are infected, albeit with
variable numbers (Fig. 1).
Helminths are a rich source of interesting mole-
cules that could lead to innovation for many aspects of
biomedicine. Recent studies of hostparasite interactions
have led to important discoveries related to the identifi-
cation of potential new targets for diagnosis and treat-
ment, as well as new vaccine targets for helminthiasis
(109,110). New helminths target molecules consist mainly
of those present at the external surface (cuticle in nema-
todes and tegument in trematodes and cestodes) and the
excretory/secretory products (ESP), where cytoskeletal
proteins, nuclear proteins and glycolytic enzymes are the
most abundant ones (110112).
Flatworms
Recently, the existence of exosome-like vesicles in the
parasitic intestinal trematodes Echinostoma caproni and
the liver fluke Fasciola hepatica has been described (112).
This constitutes the first description of exosomes in
parasitic helminths, although the existence of ‘‘membrane
bound vesicles’’ in E. caproni and MVBs in F. hepatica
were previously reported (113115). Vesicles extruding
from the tegument have been also identified in other
trematodes like the causative agent of schistosomiasis,
Schistosoma mansoni (116).
EVs are present in the worm tegument as well as in
insoluble fractions of ESP (112). The first studies on EVs
composition in E. caproni and F. hepatica have identified
51 and 79 parasitic proteins, respectively, containing more
than half of the proteins previously identified in the
secretome of E. caproni, F. hepatica and other parasitic
trematodes (110,115,117,118). Furthermore, it may ex-
plain the presence of atypical proteins lacking classical
secretion signal peptides, like enolase, in the helminths
secretions (110). More recently, the presence of tetra-
spanins as well as other typical exosome proteins in the
Schistosoma japonicum and Schistosoma mansoni tegu-
ments has been described, suggesting a similar protein
distribution in membranes of tegumentary vesicles in
these parasites (119,120). All together, these data suggests
that EVs constitute the primary mechanism for protein
export in trematodes, as reviewed here for other parasites.
Trematode EVs also contain constituent host proteins
that vary depending on the parasite species. For example,
while mucin-2 was found in E. caproni EVs, F. hepatica
EVs contained CD19 and the constant region of the IgA
heavy chain (112,115). It is noteworthy to mention that
proteomic identification is difficult in most of these orga-
nisms due to the lack of available assembled sequenced
genomes, and it relies on search engines that use transcrip-
tomic data (121,122). Marcilla et al. have also described
that EVs were not only actively released by the trematode
E. caproni, but also were up taken by intestinal cells in
culture (112), suggesting a role for these vesicles in host
parasite communication as well as in the establishment
of the infection, not only with this trematode but for a
variety of flukes and tapeworms.
The secretion and subsequent uptake of EVs provides
a mechanism of cell-to-cell communication and enables
RNA transport. Exosomes are considered the major
‘‘miRNA transporter’’ between cells, since they contain
most of the extracellular miRNAs that have been identi-
fied (123,124). Packaging of RNA (mRNA and miRNA)
in vesicles appears to provide stability and resistance to
RNAse digestion in body fluids, due to the lipid mem-
brane (125,126). More recently, the presence of miRNAs
in vesicles from another parasitic helminths, Dicrocoelium
dendriticum, have been demonstrated confirming this phe-
nomenon as a common feature in parasitic helminths
(127). EVs appear to serve as vehicles for miRNA and
other regulatory molecules, such as regulatory sequences
of mRNA, and may play an important role in the
synchronization of metabolism between the host and its
parasites regulating host gene expression. Future studies
should focus on the characterization and functional
analysis of these molecules in the host.
Roundworms
Little is known about the presence of EVs in parasitic
nematodes. A secretion pathway involving MVBs and the
release of exosomes at the apical plasma membrane from
the non-parasitic model nematode Caenorhabditis elegans,
has been described (128). Buck and co-workers have con-
firmed recently the existence of EVs in H. polygyrus,
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showing their immunomodulatory effect on a murine model
confirming previous observations with ESP from the same
nematode (129). The presence of ‘‘atypical secreted’’
proteins, including 14-3-3 and serpin, in the Ascaris
suum larval proteome have been described, suggesting
that they are secreted in EVs (130).
Although the secretion of EVs by parasitic helminths is
just beginning to be characterized, the research on secre-
tion vesicles and their involvement in intra- and extracel-
lular signallingwill addresswhether these vesicles constitute
good targets for new control strategies in helminthiases,
which could be implemented as new diagnostic and
treatment tools and vaccines.
Concluding remarks
Initially regarded as by-products of cellular metabolism,
EVs are now known to act as mediators involved in the
transmission of biological signals. In their approximately
150,000 years of co-evolution (12), human parasites have
evolved complex life cycles where intercellular commu-
nication is essential. EVs appear to play an important
role on many levels. (a) In parasite adaptation to the
changing host environment such as drug pressure and pH
changes. (b) In infectivity where possible associations
with intensity of vesicle shedding of different species have
been reported. (c) In immunomodulation where EVs have
been proposed to act as messengers for invasion, some-
how preparing the host cell for the incoming parasite. (d)
In direct regulation of the host transcriptome upon
internalization of EVs (Fig. 2). Not surprisingly, even if
research on EVs in parasites is just in its infancy, it is
already demonstrating that EVs are key players in such
intercellular communications thus contributing to chronic
infections and pathophysiology.
Research on EVs also holds great promise as new
therapeutic agents and diagnostic tools. The role of EVs
in modulating immune responses was first described in
a pioneering study using exosomes secreted by a human
B cell line (131). Since then, the immune modulatory
properties of exosomes and EVs from other cells have
been demonstrated (2). Remarkably, the use of exosomes
in human clinical trials against late-stage cancer patients
demonstrated their great potential as cell-free vaccines
(40). With regard to parasitic diseases, no clinical trials
have yet been reported; however, proof-of-principle of
Fig. 2. Extracellular vesicles (EVs) and parasitic diseases. Two major groups of parasitic diseases, protozoa and helminths, as reviewed
here actively secrete EVs of endocytic origin (exosomes, 40100 nm) or membrane budding (microvesicles, 100 nm1 mM). As
illustrated here with selected examples, they can act in different biological/pathological processes or potentially used to discover new
biomarkers for diagnostics or as cell-free vaccines. (A) Intercellular communication mediated by exosomes in Trichomonas vaginalis
(106). (B) Induction of cerebral malaria-like histopathology (37). (C) Discovery of new biomarkers for diagnostics in helminths (112).
(D) Cell-free vaccines in malaria (30).
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their potential as novel vaccines have been shown for
Toxoplasma gondii (39), Leishmania major (102) and
P. yoelii (30), where exosomes from antigen loaded DCs
or from infected cells protect animal models from
infection. Last but not least, because EVs are found in
all biological fluids (132), the molecular composition
of EVs from different origins and pathologies is already
demonstrating their great potential as biomarkers. All of
these studies, however, are presently confounded by the
lack of consensus definitions and protocols for isolation
and characterization of EVs from different cell and tissue
origins (1). Overcoming these technical difficulties will pave
the way to unveil molecular basis of pathophysiology and
to use them as novel diagnostic tools and therapeutic
agents against parasitic diseases.
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